irinotecan,leucovorin,oxaliplatin,nab-paclitaxel,gemcitabine
Ipsen
[]
#gi23: napoli 3 trial in pancreas cancer shows nalirirfox has higher response rate and significantly longer os (11.2 vs 9.1 mo, p=0.04) and pfs than gemnabp first-line therapy. new upfront option for fit patients. 
Academic GI Cancer Centre in the City of London. Delivering evidence-based treatments and clinical trials to patients. Informing and education patients and HCPs